Fiscal Year 2024 Department of Defense Toxic Exposures Research Program (TERP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Investigator-Initiated Research Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: HT942524TERPIIRA	Independent intramural (Department of Defense [DOD]) and extramural investigators at all academic levels (or equivalent)	 NEW for FY24: Pre-application submission is required; full application submission is by invitation only. Supports studies that will make an important contribution toward research and/or patient care for a disease or condition associated with military-related toxic exposures. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. New Approach Methodologies may also be used. Research involving human subjects and human anatomical substances is permitted. Impact is an important aspect of the Investigator Initiated Research Award. Must address at least one of the FY24 TERP Program Goals. Must address at least one of the FY24 TERP Topic Areas. Collaboration with DOD and/or U.S. Department of Veterans Affairs (VA) researchers and clinicians is encouraged. Preliminary data are required. 	 The maximum allowable funding for the entire period of performance is \$500,000 for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 3 years. 	Pre-Application (Preproposal): August 13, 2024 5:00 p.m. Eastern time Application: November 12, 2024 11:59 p.m. Eastern time

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Translational Research Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: HT942524TERPTRA	Extramural and intramural (DOD) investigators at or above the level of Assistant Professor (or equivalent) Partnering Principal Investigator (PI) Option: Partnering extramural and/or intramural (DOD) investigators at or above level of Assistant Professor (or equivalent)	 NEW for FY24: Pre-application submission is required; full application submission is by invitation only. Supports translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications including health care products, interventions, technologies, and/or clinical practice guidelines. Research involving human subjects and human anatomical substances is permitted. Clinical trials are not permitted. Impact and Translational Potential are important aspects of the Translational Research Award. Must address at least one of the FY24 TERP Program Goals. Must address at least one of the FY24 TERP Topic Areas. Participation of at least one military or Veteran consumer as a member of the research team is strongly encouraged. Collaboration with DOD and/or VA researchers and clinicians is encouraged. Preliminary data are required. Partnering PI Option: Up to three PIs may partner in one overarching study. 	 The maximum allowable funding for the entire period of performance is \$800,000 for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 3 years. Partnering PI Option: The maximum allowable funding for the entire period of performance is \$1,600,000 for combined direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 3 years. 	Pre-Application (Preproposal): August 13, 2024 5:00 p.m. Eastern time Application: November 12, 2024 11:59 p.m. Eastern time

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Clinical Trial Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: HT942524TERPCTA	Extramural and intramural (DOD) investigators at or above the level of Assistant Professor (or equivalent) Partnering PI Option: Partnering extramural and/or intramural (DOD) investigators at or above level of Assistant Professor (or equivalent) Professor (or equivalent)	 NEW for FY24: Pre-application submission is required; full application submission is by invitation only. Supports the rapid implementation of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases, or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Clinical trials are expected to be initiated within 12-18 months of the award date. Preclinical studies (including animal research) are not permitted. Clinical Impact is an important aspect of the Clinical Trial Award. Must address at least one of the FY24 TERP Program Goals. Must address at least one military or Veteran consumer as a member of the research team is strongly encouraged. Collaboration with DOD and/or VA researchers and clinicians is encouraged. Collaboration with DOD and/or VA researchers and clinicians is encouraged. Inclusion of at least one clinician on the study team is strongly encouraged. Preliminary data are required. Partnering PI Option: Up to three PIs may partner in one overarching study. 	 The maximum allowable funding for the entire period of performance is \$1,500,000 for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 4 years. Partnering PI Option: The maximum allowable funding for the entire period of performance is \$2,500,000 for combined direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 4 years. 	Pre-Application (Preproposal): August 13, 2024 5:00 p.m. Eastern time Application: November 12, 2024 11:59 p.m. Eastern time